ABOUT MILLIPORESIGMA
The growing demand for new therapies, persistent pressure to reduce costs, and the clinical success of novel modalities are driving the biopharmaceutical industry to adopt new strategies to increase the speed, efficiency, and agility of manufacturing. A variety of approaches are available to address these imperatives.
Monoclonal antibodies (mAbs) and recombinant proteins have templated production workflows. Here, the focus is on exploring and integrating strategies defined by Biopharma 4.0 – the digital transformation to intensified, closed, connected, or continuous processing. For these companies, the key question is: “Where do I begin?”
In contrast, relatively new modalities such as mRNA and cell and gene therapy present different challenges. Cell and gene therapies are highly complex, lack a manufacturing template, and innovators must operate in a regulatory environment that continues to evolve. When developing and manufacturing mRNA-based therapeutics, among the most pressing objectives are to improve process efficiency and mRNA product stability.
For innovators of these novel modalities, access to new technologies and a breadth of expert services are critical success factors as they ask: “How can I improve my process?”
MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany, empowers you to optimize and streamline your development and manufacturing processes. Whether you are producing mAbs and recombinant proteins, or highly complex, novel modalities, we will help you meet your goals for speed, efficiency, and agility.
We offer a convergent end-to-end portfolio of advanced, closed processing-ready technologies with extensive documentation for upstream and downstream operations, process analytical technologies (PAT), data analytics, automation and control software, contract testing and analytical development services, non-GMP environment labs, and CTDMO services for mAbs, high potency active pharmaceutical ingredients (HPAPIs), antibody drug conjugates (ADCs), mRNA, and lipid nanoparticle (LNP) formulation.
HOT PRODUCTS
-
Designed to purify biologics at clinical and process scale, the Mobius® FlexReady Solution with Smart Flexware® Assemblies is flexible, allowing you to have a single system for tangential flow filtration (TFF) at various scales.
-
To ensure optimum equipment uptime and regulatory compliance while mitigating risks, MilliporeSigma has developed System Service Reliance Plans; a complete range of services for your systems and equipment. These comprehensive service and support packages allow you to select a coverage level that best fit your needs
-
MilliporeSigma’s Mobius® single-use mixing solutions deliver advanced technology for mixing pharmaceutical ingredients from intermediate to final drug products and for the preparation of process solutions, such as buffers and media. Unlike traditional stainless-steel mixers, single-use mixers reduce downtime due to CIP, SIP, cleaning validation, and process engineering. Mobius® single-use mixing solutions also offer operational flexibility as they can be up and running in less than five minutes. They are capable of mixing speeds up to 1000 RPMs meeting the broadest range of mixing production requirements. Mobius® flexibility offers you a choice of just the right filter, connector, tubing options for your specific application and environment, including sterile interfaces, from fermentation to final fill. Sizes range from 10 L to 3000 L.
-
You’re developing lifesaving gene-modified cell therapies and need to manufacture lentiviral vector as quickly as possible. But scale-up and regulatory hurdles make the path to the clinic slow and labor intensive.
We're here to help.
-
From your bioreactor to final sterile filtration, the new NovaSeptum® GO sampling system lets you sample processes the way you want. Flexible formats and volumes adapt to your process for robust, reliable monitoring and quality assurance.
-
Cell culture media are important for process efficiency and mAb quality. Production media support initial cell growth and production, while the feeds replenish depleted nutrients required for cellular function and maintain and extend the production phase in fed-batch mode.
-
Cellvento® CHO media are designed to support growth and maintenance of specific CHO cell lines in suspension cell culture for expression of monoclonal antibodies and recombinant proteins. The new Cellvento® 4CHO-X Expansion Medium supports cell expansion including N-1 perfusion for Chinese Hamster Ovary (CHO) cell lines.
-
In recent years, the development of media used to expand and mature adult stem cells has greatly increased the success rate of adult stem cell therapy and the breadth of potential stem cell-based therapies. To obtain enough cells, ex vivo expansion has been utilized to ensure successful engraftment and economize the manufacture of both allogeneic and autologous therapies.
-
Bio4C ProcessPad™ software is a data collection, visualization, and analytics software platform that facilitates 21 CFR Part 11 compliance and enables bioprocess monitoring, lifecycle management, reporting, investigations, and continued process verification (CPV).
-
The benchtop Cellicon™ Perfusion Solution is designed to meet your perfused seed train challenges.
BROCHURES
- Amplified Innovation, Amplified Impact
- Small Volume Custom Media
- BioRepository Services
- Empower Your Studies With Our Expertise
- Starting Point Of Every Success Story
- Ensure Complete Characterization Of Your Rodent Cell Line
- High‑Purity Nucleoside Triphosphates
- Chemicals For mRNA Drug Manufacturing
- Gene Therapy Capabilities For AAV And Lentivirus Production Platforms
- NGS AAT For Cell Line Characterization
WEBINARS AND PODCASTS
PRODUCT GUIDES, DATA SHEETS & APPLICATION NOTES
- Microbial Integrity Of Sampling Systems After Multiple Actuations
- Evaluation Of TFF Operating Control Strategies And Scalability
- High‑Purity Nucleoside Triphosphates
- Seamless Workflow For Environmental Monitoring
- Accelerate LNP Manufacturing With Automated Process Development
- Application Of A Dual Spiking Strategy In Viral Clearance Studies
- Multi-Column Chromatography For Efficient Polishing Purification
- A Sustainable Future: Phasing Out Animal Testing
- Discover The Mobius® Multi Column Capture System
- Virus Retention Performance Under Diverse Processing Conditions
NEWS
- MilliporeSigma Introduces Comprehensive AAV Express Platform For Streamlined Gene Therapy Production
- Simtra BioPharma Solutions And MilliporeSigma Announce Strategic Alliance For Antibody Drug Conjugates Drug Substance And Drug Product Manufacturing Services
- MilliporeSigma Invests $76 Million To Expand ADC Manufacturing For Novel Cancer Therapies
- MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
- MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
- MilliporeSigma Accelerates Readiness Of Bioprocessing Facility Of The Future
CONTACT INFORMATION
MilliporeSigma
400 Summit Drive
Burlington, MA 01803
UNITED STATES
Phone: 978-762-5100
NAVIGATING THE EMERGING BIOTECH ECOSYSTEM
FEATURED ARTICLES
-
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
Repeated sampling doesn’t have to mean increased contamination risk. See how microbial ingress testing demonstrates sterility integrity after up to 50 sampling actuations.
-
Gain insight into a comparison of TMP and permeate control strategies for viral vector TFF, highlighting impacts on flux, processing time, impurity removal, and scale-up predictability across development.
-
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Learn how connected sampling tools and compliant monitoring software improve data integrity and streamline compressed gas testing workflows, offering a path to reliable environmental monitoring.
-
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.
-
Explore how an alternative spiking strategy can streamline viral clearance studies, reduce material demands, and maintain compliance while addressing the challenges posed by MLV and MMV.
-
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
Intensify your mAb manufacturing with optimized media, advanced filtration, and real-time analytics. Learn how integrated upstream and downstream solutions boost productivity and reduce costs.
-
Boost downstream efficiency with multi-column chromatography for polishing to achieve higher productivity, reduced resin costs, and automated operation while maintaining purity and recovery.
-
Discover a practical roadmap for replacing animal tests with advanced molecular methods, as well as how regulatory updates and innovative technologies are shaping a sustainable future.
-
Virus filtration is robust across a wide range of process parameters, including high protein concentration and flow decay. Discover how retention relies on size exclusion to simplify risk assessment.
-
Strategic, well-aligned partnerships between sponsors and CDMOs are key to efficient, scalable viral vector technology transfer.
-
Aseptic fill and finish operations gain efficiency and precision with modular isolator technology, inline weight checks, and lyophilization, which are ideal for mRNA-LNPs and other sensitive modalities.
-
Cell culture performance remained consistent across PES and PVDF filters, even under worst-case filtration conditions. Discover a practical framework for evaluating membrane impact on CHO cell growth.
-
AAVs are reshaping gene therapy, but scaling production introduces complexity. Learn how upstream process optimization can improve yield, consistency, and speed to meet growing demands.
-
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety.
-
Ensure consistency and quality in production with an advanced CCM fingerprinting technique that is capable of identifying over 100 media components to reduce variability and meet regulatory standards.


